-+ 0.00%
-+ 0.00%
-+ 0.00%

Cabaletta Bio posts corporate presentation on CD19 CAR-T candidate rese-cel in autoimmunity

PUBT·04/20/2026 11:07:23
Listen to the news
Cabaletta Bio posts corporate presentation on CD19 CAR-T candidate rese-cel in autoimmunity
  • Cabaletta Bio highlighted rese-cel (CABA-201), an autologous CD19 CAR-T therapy, as its lead program aimed at delivering curative targeted cellular therapies for autoimmune diseases.
  • Pivotal RESET-Myositis study is enrolling with a 17-patient single-arm registrational cohort; company targets 2027 BLA submission.
  • Phase 1/2 readouts are expected in 1H26 for systemic sclerosis plus systemic lupus erythematosus, including lupus nephritis.
  • Safety data across first 40 patients dosed with preconditioning showed 95% with no CRS or Grade 1 CRS; 95% had no ICANS.
  • Strategy centers on eliminating preconditioning plus shifting to automated manufacturing via Cellares during 2026 to support outpatient use and scale to thousands of patient runs per year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.